(17) Patients with Methamphetamine-Associated Pulmonary Arterial Hypertension Have Less Favorable Hemodynamics Than Other Patients with Group 1 PAHĮ. KG, Essen, Germany, 7Global Clinical Development, Bayer AG, Berlin, Germany, 8Global Medical Affairs, Bayer AG, Berlin, Germany, 9Clinic for Respiratory Medicine, Hannover Medical School, member of the German Center for Lung Research (DZL), Hannover, Germany 1Ohio State University, Columbus, OH, 2Pulmonary Hypertension Center, Boston University/Boston Medical Center, Boston, MA, 3Department of Medicine, Houston Methodist, Houston, TX, 4Member of the German Center for Lung Research (DZL), University of Giessen and Marburg Lung Center (UGMLC), Glessen, Germany, 5Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, 6CHRESTOS Concept GmbH & Co. (16) Validation of REVEAL Risk Score Calculator 2.0 in Patients with PAH in the Phase III PATENT Study 1Division of Cardiology, Sinai Health System, Toronto, ON, Canada, 2Division of Respirology, University Health Network, Toronto, ON, Canada (15) The Relationship between Pulmonary Artery Pulse Pressure and Pulmonary Artery Wedge Pressure during Exercise in Health and in Patients with Suspected Pulmonary Hypertension 1Pulmonary, Tufts Medical Center, Boston, MA, 2Arizona Pulmonary Specialists, Phoenix, AZ, 3Houston Methodist Hospital, Houston, TX, 4University of Texas Health Sciences Center at San Antonio, San Antonio, TX, 5Liquidia Technologies, Morrisville, NC, 6Anschutz Medical Campus, University of Colorado Denver, Aurora, CO (14) INSPIRE: Final Results from a Phase 3, Open-Label, Pivotal Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension 1Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands, 2David Geffen School of Medicine at UCLA, Los Angeles, CA, 3Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, 4Royal Hallamshire Hospital, Sheffield, United Kingdom, 5Almazov National Medical Research Centre, St Petersburg, Russian Federation, 6Scottish Pulmonary Vascular Unit, Glasgow, United Kingdom, 7Massachusetts General Hospital and Harvard Medical School, Boston, MA, 8Department of Pulmonary Circulation CMKP at European Health Center, Otwock, Poland, 9Heart Center at the University of Cologne, and Cologne Cardiovascular Research Center (CCRC), Cologne, Germany, 10Department of Experimental, Diagnostic and Specialty Medicine – DIMES, University of Bologna, Bologna, Italy (12) Results from the REPAIR Study: Effects of Macitentan on Right Ventricular (RV) Remodelling in Pulmonary Arterial Hypertension (PAH)Ī. Liaison, ISHLT 2020 Program Committee PH Group Oksana Shlobin, MD, Inova Fairfax Hospital, Falls Church, VA, USA Sarah Medrek, MD, University of New Mexico, Albuquerque, NM, USA In addition, we investigated whether a high probability of heart failure with preserved ejection fraction, assessed by the H 2 FPEF score (obesity, atrial fibrillation, age >60 yrs, 2 antihypertensives, E/e' >9, and pulmonary artery systolic pressure by echo >35 mmHg), similarly predicted the presence of elevated pulmonary artery wedge pressure.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |